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Abstract: A growing body of evidence emphasizes the important role exosomes in different
physiological and pathological conditions. Exosomes, virus-size extracellular vesicles (EVs), carry a
complex molecular cargo, which is actively processed in the endocytic compartment of parental cells.
Exosomes carry and deliver this cargo to recipient cells, serving as an intercellular communication
system. The methods for recovery of exosomes from supernatants of cell lines or body fluids are not
uniformly established. Yet, studies of the quality and quantity of exosome cargos underlie the concept
of “liquid biopsy.” Exosomes are emerging as a potentially useful diagnostic tool and a predictor of
disease progression, response to therapy and overall survival. Although many novel approaches
to exosome isolation and analysis of their cargos have been introduced, the role of exosomes as
diagnostic or prognostic biomarkers of disease remains unconfirmed. This review considers existing
challenges to exosome validation as disease biomarkers. Focusing on advantages and limitations of
methods for exosome isolation and characterization, approaches are proposed to facilitate further
progress in the development of exosomes as biomarkers in human disease.
Keywords: exosomes; extracellular vesicles (EVs); exosome isolation; biomarkers; drug delivery;
tumor-derived exosomes (TEX)
1. Introduction
Exosomes are virus-size membranous vesicles ranging in the diameter from 30–150 nm. They
originate from the endocytic compartment of the producer cell. A growing body of evidence indicates
that exosomes play a major role in intercellular communication in physiological as well as pathological
conditions [1]. The rapidly increasing number of publications emphasizes the growing interest in
explorations of biologic functions of exosomes. Compared to microvesicles (MVs), which are secreted
by “budding” or “pinching off” from the cell membrane surface, the biogenesis of exosomes is more
complex. It involves reverse membrane invagination and processing in multivesicular bodies (MVBs),
followed by exosome release into intercellular fluid when MVBs fuse with the cell membrane [2]. Due
to the endosomal origin, exosomes are enriched in late endosome components such as CD63, CD9
and CD81 [3]. The complex biogenesis suggests that exosomes, whose cargo reflects the molecular
processing taking place inside the parent cell, are best suited to serve as potential surrogates of this
parent cell in body fluids. The fidelity of exosome cargo with that of the parent cell has been confirmed
in several studies [4]. Analysis of exosome levels in body fluids of patients and of exosome cargos
emerges as a potential diagnostic tool of disease or predictor of disease progression, response to
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therapy and overall survival [5–7]. Since exosomes can be isolated from all body fluids, they are
optimal candidates for analysis as part of a non-invasive liquid biopsy [8]. A therapeutic application
of exosomes has also been suggested for different diseases, utilizing their biological activity and the
rich cargo they carry to serve as potential cell-free therapy [9]. Exosomes have been implicated in
drug resistance and in reprogramming of tissue environments in various diseases [10–12]. Universal
exosome involvement in cellular interactions creates an urgent need for a better understanding of their
characteristics and functions. Hence, the isolation and molecular/genetic analyses of exosomes are
currently a priority.
Studies of body fluid-derived exosomes are a challenge, since the isolated exosomes are derived
from many different cell types and contain components of body fluids (“contaminants’), which have
to be removed during exosome isolation. Most of what is currently known about exosomes comes
from studies of cell lines propagated in long-term cultures. This offers an opportunity of examining
exosomes derived from a single, well-defined cell type [13]. However, recent technological progress in
exosome isolation and their analysis has not led to a universally accepted recommendation for exosome
isolation. The field is facing problems in selecting and reproducing various isolation methodologies.
Additionally, approaches to data acquisition/analysis vary widely. The recommendations formulated
in the guidelines of the International Society for Extracellular Vesicles (ISEV) are vague and leave
extracellular vesicles (EV) isolation to investigators’ discretion [14]. This situation reflects the young age
of the fast-developing EV field and the recommendations by ISEV are produced as a community effort
which involves the leading EV researchers. The guidelines go on to note that some major conclusions
in published literature are often insufficiently supported by the reported experimental evidence. For
these reasons, the guidelines charge the investigators to closely specify the utilized methodologies
presumably to accumulate the described data for formulating future recommendations [14].
Not only exosome isolation methods, but also the nomenclature of EVs remains unclear. The
recent introduction of exomeres (<30 nm in diameter), in addition to small and large exosomes, all
with potentially similar biogenesis, and larger EVs (>200 nm), encompassing microvesicles, oncosomes
and apoptotic bodies, emphasizes the heterogeneity of EVs [15]. Recognizing the existing uncertainty
and confusion in the EV field, we highlight and summarize the challenges facing exosome research
today. The focus is on the methodologies for exosome isolation, the influence of cell culture parameters
on the quantity and quality of isolated exosomes and the consequences of different treatments of the
parental cells on exosome production. The current technologies for the analysis of the exosome cargo
and their limitations will be discussed and solutions for improvements will be considered.
2. Influence of Exosome Isolation/Purification Methodologies on the Composition of
Exosome Cargos
In the field of EV research, no gold standard for exosome isolation exists, and new methodologies
seem to appear almost daily. Ultracentrifugation (including differential centrifugation) remains by
far the most widely used primary isolation method for EVs, being used by more than 80% of all EV
researchers worldwide [16]. Although ultracentrifugation is widely used in the field, the technique has
several drawbacks, including the co-isolation of non-exosomal impurities, low reproducibility, low
RNA yield, potential damage of exosomes and low-throughput of samples, which is not compatible
with clinical utilization [17]. Investigators who exclusively use conditioned culture media for exosome
isolation mostly use ultracentrifugation, whereas those studying complex biological fluids, such as
plasma, tended to use a combination of different methods for isolation and purification of EVs. Among
these methods are density gradient centrifugation at lower speeds to remove cell fragments and large
platelet-derived vesicles, followed by ultrafiltration and size-exclusion chromatography (SEC) [16].
Each of the multiple isolation methods available today has advantages and disadvantages and absolute
exosome purity remains an unrealistic goal that is only partially met by methods such as SEC, which
removes considerable (but not all) quantity of “contaminating’ plasma or medium components [13].
Recently, Lyden’s group introduced a new method for EV isolation based on asymmetric-flow field-flow
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fractionation (AF4). Using AF4, nanoparticles are separated based on their density and hydrodynamic
properties by two perpendicular flows, i.e., the forward laminar channel flow and the variable crossflow.
This method allowed for the identification of exomeres as well as two exosome subpopulations that
demonstrate distinct biophysical and molecular properties [15]. This and similar discoveries will
accelerate the successful performance of translational studies mediated by EV subsets in diagnostic,
prognostic and therapeutic applications.
The method used for EVs isolation from body fluids is critical for the characterization of their
cargo. Reports in the literature suggest that different isolation methods introduce variations in the
concentration, purity and size of exosomes [18–20]. Exosomes isolated by ultracentrifugation, ExoQuick
or Total Exosome Isolation Reagent yielded mRNA that showed differences upon subsequent RNA
sequencing analysis. Although 588 common miRNAs were found in all three exosome samples, each
sample isolated by the different method contained approximately 200 miRNAs, which were unique
for each exosome preparation [18]. Ding et al. reported similar results showing that the exosomal
miRNA profiles are distinct, depending on the isolation methods used [21]. Additional evidence was
provided by Rekker et al., who also concluded that the miRNA profile in exosomes may be altered by
the isolation method [22]. Proteomic or flow cytometry-based analyses of exosomes yielded similar
results, suggesting that isolated exosome fractions are often “contaminated” by co-isolated plasma
proteins and that the extent of contamination depends on the isolation method used [16]. Common
co-isolated soluble proteins are albumin, immunoglobulins and matrix metalloproteases (MMPs), all
of which are abundantly present in body fluids [23,24]. The available data lead to the conclusion that
approaches to exosome isolation from plasma or body fluids remain the most critical aspect for the
characterization of exosome molecular or genetic cargos. Thus, it is necessary to proceed with caution
in selecting the appropriate purification method for EVs, and to carefully discriminate between the true
exosome content versus “contaminating” plasma proteins or nucleic acids coating the exosome surface.
Isolation of exosomes by direct immunocapture from cell culture supernatants or body fluids
might overcome the ”contamination” problem; however, immune capture is strictly dependent on
specific binding of the detection antibody to an antigen on the exosome surface. Therefore, the presence
of “contaminants” is likely to interfere with immune capture. We have reported that immunocapture
of exosomes after their isolation from plasma by, e.g., size exclusion chromatography (SEC), which
eliminates most, but not all, of contaminants, might reduce the interference by non-EV-associated
proteins [25]. The use of mass spectrometry (LC-MS/MS) for detection of exosome-associated proteins
is widely used. However, it is important to acknowledge that mass spectrometry might provide
artefactual results due to contaminations of exosomes with high-abundance plasma proteins that can
mask low-abundance exosome-specific components [26]. Various functional studies performed with
plasma-derived exosomes also showed that functions of the isolated exosomes may be negatively
influenced by “contaminating”, non-vesicular materials [23].
Furthermore, comparisons of different isolation techniques indicated that altered levels of several
proteins widely used as “markers” of exosomes, such as tetraspanins, varied among different isolation
techniques [27] and between exosomes derived from different tumor cells [13]. Exosome markers
may be differential due to different EV isolation methods producing different purity, but also because
they may isolate different subpopulations of EVs. Similar results were also observed for angiogenic
factors, which were present at significantly different levels in a study comparing ultracentrifugation
and SEC [23]. The reason for these altered levels of protein “markers” may again be due to the ratios of
EV/non-EV components in the cargo of the isolated exosomes.
In aggregate, the “purity” of exosome samples is highly dependent on the vesicle isolation method,
and it is likely to affect results interpretation. However, highest purity usually comes in expense of low
yield and for some biomarker studies, the purity, i.e., where the biomarker came from (EVs/co-isolating
matrix), may not matter if the biomarker is reproducibly detected in the EV preparations. For some
applications, such as proteomic analyses, it is possible that the analyses of exosome cargo might not
be able to identify proteins present in femtomolar quantities in exosomes, especially in the presence
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of “contaminating” proteins. The solution may be amplification of these proteins using monoclonal
antibodies, which will detect the ‘rare’ exosome components with exquisite specificity, as we and
others have demonstrated [28].
3. Culture Conditions Influence Exosome Levels and Cargo
The cell culture conditions used for exosome production vary greatly among laboratories, even
when well-established cell lines are used. The yield and cargo of exosomes can be drastically altered by
culture conditions used for producer cell lines. Finding the optimal conditions for exosome production
by a specific cell type remains a challenge, since it is always a compromise between optimal conditions
for growth and those for exosome production and isolation. Different parameters of cell culture can
influence the cargo composition of exosomes as illustrated below.
3.1. Culture Containers
Comparisons of exosomes derived from cells cultured in conventional cell culture dishes versus
two-chamber bioreactors indicated that the morphology, size distribution and surface markers of
exosomes were similar. However, the yield of exosomes was more than 100 times higher in bioreactors
than in dishes, and the metabolomic analysis revealed statistically significant differences [29].
3.2. Cells
Each cell type requires unique medium composition for optimal growth and unique seeding
density, passage frequency and medium replacement. As alluded to already, the requirements for
cell growth have to be harmonized with the requirements for the exosome isolation and optimized
for the intended downstream applications [26]. A prerequisite for any EV-related study is the use
of contamination-free cells. Mycoplasma or other microbes can also release EVs interfering with the
results of exosome characterization, cargo analysis or functional studies [30–32].
The passage number can impact the cargo composition and functions of exosomes, as shown for
mesenchymal stromal cells (MSCs). Within five serial passages, the level of the exosome “marker” CD63
was reduced, and the recovered exosomes were less potent in stimulating migration of endothelial
cells [33]. Umezu et al. compared exosomes derived from bone marrow stromal cells of normal human
donors and reported that exosomes derived from older donors showed significantly lower functions
than those derived from younger donors [34]. Cells maintained in long-term cultures and undergoing
numerous passages are likely to differ in exosome production.
Numbers of cells seeded to initiate cultures are very important for exosome production and
their “purity”. It has been reported for several different cell lines that 36h of subconfluency and
36h of confluency during a 72h incubation period resulted in sufficient exosome yields and reduced
“contaminations.” Seeding higher cell numbers decreased the levels of exosomes per cell and increased
contamination with medium-derived proteins [13]. Besides regulating the sample purity, the use of
different cell numbers can have a direct impact on the cargo and functions of exosomes, as shown
by Patel et al. [33]. Therefore, to guarantee the reproducibility and constancy of levels and cargo of
the isolated exosomes, it is necessary to establish and utilize the same cell seeding protocol. Using a
similar passage of producer cells further ensures the constancy of exosome quality [13].
3.3. Medium Composition
The medium used for cell culture and exosome recovery from supernatants emerges as a crucial
factor in exosome production. All medium components influence the production and/or composition
of exosomes; this emphasizes the importance of choosing the right components and reporting them
in the publications. The medium composition has to be harmonized with the intended vesicle use
and desired exosome “purity”. The medium that best supports growth of producer cells and yields
exosomes with a reproducibly stable cargo should be selected and consistently used for culture of
exosome producer cell lines.
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The levels of glucose used in culture media play an especially important role in exosome production.
Burger et al. demonstrated that high glucose levels enhanced EV production and promoted secretion of
bigger vesicles sized at 250 nm. A proteomic exosome analysis indicated that the high glucose content
significantly altered the molecular composition of EVs, resulting in the presence of exosome proteins,
which induced activation of molecular pathways in recipient cells that differed from those induced by
EVs derived from cells cultured with lower glucose levels [35]. Similar results were reported by Rice et
al., who also measured increased exosome production under high glucose and described an altered
bioactivity of exosomes derived from high versus low glucose conditions [36]. On the other hand,
glucose starvation also increased exosome secretion and changed the protein content. Gene Ontology
(GO) analysis demonstrated different biological processes associated with the protein pattern found in
exosomes from conditioned medium with or without glucose starvation [37].
Antibiotics are another widely used component of culture media. It was shown that ciprofloxacin,
which is broadly used in cell cultures to control mycoplasma contamination, increases the level of DNA,
which is associated with exosomes and is carried on the surface of the vesicles. Exosomes derived
from ciprofloxacin-treated cells showed a DNA-dependent binding to fibronectin [38].
Of major importance are medium components, which are highly enriched in proteins and contain
EVs, such as fetal bovine serum (FBS). Exosomes present in FBS were reported to be biologically-active,
and their co-isolation might lead to interference in subsequent in vitro or in vivo studies [39]. Thus far,
no standardized protocol for the exosome-depletion of FBS exists, and different research groups use
various approaches to depletion of bovine exosomes from sera. One approach is to culture cells in in
serum-free medium during the exosomes-release period; however, the missing FBS can lead to extensive
starvation of the cells, can change the cellular behavior and the composition of secreted exosomes [26,40].
Although cells cultured in serum-free media did not result in EVs with significantly different biophysical
or size differences as compared with cells cultured in serum-containing media, the quantity of isolated
EVs was greatly altered. Moreover, the levels of certain vesicular proteins (e.g., small GTPases,
G-protein complexes, mRNA processing proteins and splicing factors) were found to be different in
EVs produced under different culture conditions [41]. The use of commercial exosome-depleted FBS is
another alternative. However, the manufacturer usually does not describe the method used for exosome
depletion. Therefore, the ISEV guidelines recommend the utilization of home-generated depletion
protocols instead, provided the protocol used is described in detail [14]. A variety of protocols are
available for exosome depletion of FBS; most involve extensive ultracentrifugation or filtration [42,43].
These protocols may result in a loss of growth factors present in FBS, decreasing its growth-promoting
effects. Since a full depletion of EVs may not be possible, the ISEV guidelines recommend the use of
fresh media not cultured with cells as controls in downstream exosome assays [14]. Specific miRNAs
abundant in FBS, such as miR-122, miR-451a and miR-1246, have been previously reported to be
enriched in cell culture-derived EVs, emphasizing the potentially confounding effect of the FBS on
results of highly sensitive gene expression profiling technologies [44]. In addition, not only FBS in
culture supernatants but also proteins present in serum or plasma or any body fluid used as a source
of EVs can “contaminate” exosomes leading to artefactual data in downstream applications, especially
in mass spectrometry [26].
Since the exosome isolation from conditioned media containing FBS can lead to the co-isolation
of exogenous EVs, it was suggested that cells can be cultured without serum using platelet lysates,
pituitary extracts, bile salts or synthetic factors instead [14]. However, growth factors might exert
regulatory effects on the exosome release. For example, Zhou et al. investigated the role of EGF on
exosome production [45]. They reported that the production was significantly decreased in cells treated
with EGF, but it increased after treatment of the cells with gefitinib (EGFR inhibitor).
3.4. Hypoxia
Hypoxia is an important environmental factor that affects exosome production. It was shown,
that the exosome secretion is elevated under hypoxic conditions [13,46]. Moreover, hypoxia altered
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the exosome cargo largely by changing the oxygenation status of the producing cells [4]. The
levels of exosomal markers such as tetraspanins can be altered under hypoxic conditions as recently
described [13]. Additionally, several exosomal miRNAs were found to be up-regulated. For example,
exosomes secreted by cardiosphere-derived cells under hypoxia had increased levels of pro-angiogenic
miRNAs such as miR-126, miR-130a and miR-210 [47]. Kucharzewska et al. described several
pro-angiogenic proteins, which were carried at higher levels by exosomes derived from hypoxic
cells. The hypoxia-derived exosomes also had higher activity in the in vitro and in vivo angiogenesis
assays [4].
3.5. Treatments/Perturbations of Cells
It has been reported that the formation of MVBs and the release of exosomes by producer
cells is dependent on the intracellular calcium concentration. Monensin, which is a Na+/H+
exchanger that induces changes in intracellular calcium, was shown to stimulate exosomes release
in a concentration-dependent manner [48]. In contrast, GW4869, a neutral sphingomyelinase 2
inhibitor, was shown to block exosome release in vitro and in vivo [49,50]. Another factor, which
modulates exosome release, is heparanase. The expression of this enzyme is upregulated during
tumor progression and enhanced heparanase expression or exposure of cells to exogenous heparanase
stimulates exosome secretion. Interestingly, heparanase also modulates the exosome cargo composition,
as seen by an enrichment of syndecan-1, VEGF and hepatocyte growth factor in exosomes and an
increased biological activity in functional studies [51]. Datta et al. used a high-throughput screen
to identify compounds which directly modulate exosome biogenesis in vitro. Testing a total of 4580
pharmacologically active compounds, they identified 22 compounds that either stimulated or reduced
exosome production. The authors validated the lead compounds tipifarnib, neticonazole, climbazole,
ketoconazole and triademenol as potent inhibitors and sitafloxacin, forskolin, SB218795, fenoterol,
nitrefazole and pentetrazol as activators of exosome production [52]. These findings indicate that some
of the commonly used drugs could be re-utilized for targeting the exosome biogenesis and may also
have the potential to modulate the cargo composition of exosomes.
Oxidative stress has also been described as a stimulator of exosome production. Atienzar-Aroca
et al. applied oxidative stress to cells by exposing them to increasing concentrations of ethanol. The
cellular response was a two-fold increase of exosome production, and the exosomes carried higher
levels of VEGFR in the membrane as well as an extra cargo of VEGFR mRNA in the lumen [53].
Hyperthermia represents another factor, which alters exosome composition and levels. Exosomes
derived from heat-stressed tumor cells were enriched in chemokines, such as CCL2, CCL3, CCL4,
CCL5 and CCL20 and attracted immune cells in vitro and in vivo [54].
In summary, exosome production by cells and exosome molecular content appear to be regulated
by a variety of factors and conditions. Cultured cell lines represent an important resource for studies
of exosomes. However, EVs, including exosomes, show a high degree of plasticity in their cargo and
the molecular and genetic analyses of EV-associated components remain challenging.
As in vitro production of exosomes by cell lines is strictly dependent on the producer cell growth
and metabolism, the utilization of pre-tested, standardized cell culture conditions is a necessary
requirement for obtaining sufficient and reproducible exosome preparations.
4. Disease-Associated Alterations in Exosome Production/Cargo
The levels and cargos of exosomes produced by cultured cells can be readily modulated by
environmental factors or pharmacological treatments. It is thus reasonable to expect that levels and
molecular cargos of exosomes isolated from blood or other body fluids of patients with various diseases
might be altered having been produced by diseased cells.
Indeed, numerous studies have shown that patients with different types of cancer have elevated
levels of circulating exosomes in their blood [46]. The presence of tumor-specific proteins in the cargo
of circulating exosomes confirms that these exosomes are derived from tumor cells [55]. The protein
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profile of tumor-derived exosomes (TEX) shows a high degree of plasticity and is likely modulated
by cancer therapeutics and/or by cargo alterations occurring during disease progression [6]. Similar
observations have been made for other diseases such as HIV. Levels of plasma exosomes were increased
in HIV-positive patients compared to healthy donors, and plasma-derived exosomes of HIV patients
carried proteins related to immune activation and oxidative stress [56]. Interestingly, the treatment
with antiretroviral drugs increased exosomes production and altered their content [57]. It has also
been established that the onset of critical illnesses, such as acute lung injury, acute kidney injury,
acute myocardial injury or sepsis, is associated with increased levels and altered molecular profiles
of circulating exosomes. In nearly all of these diseases, specific exosome-associated proteins or miRs
have been identified as potential disease biomarkers [58]. An example is provided by endothelial
cell-derived exosomes, which carry high levels of atherosclerosis-promoting proteins and thus have
been considered as diagnostic biomarkers for patients with cerebrovascular disease [59].
Effects of Cancer Therapeutics on EV Production, Content and Function
A growing body of evidence suggests that novel as well as conventional cancer therapies exert
profound impact on exosome secretion and their cargo composition [6,60]. These studies indicate
that exosome levels as well as their cargos might be utilized to predict responses to therapy and even
outcome. Thus, plasma exosomes have a potential to serve as predictive biomarkers in cancer. Recently,
Keklikoglou et al. demonstrated that cytotoxic chemotherapy in breast cancer enhances the production
of exosomes, upregulates the levels of annexin A6 in exosomes and promotes a pre-metastatic niche
formation caused by exosomes [60]. Similar findings were reported by Bandari et al. who demonstrated
that chemotherapy-induced exosomes have a proteome profile that is distinct from that in cells not
exposed to the drug. The authors showed that exosomes secreted by cells undergoing chemotherapy
have dramatically altered functions and promote chemoresistance, tumor survival and progression [61].
Monitoring exosomes derived from the plasma of patients with acute myeloid leukemia (AML)
indicated that the patients have high levels of TGF-β1 on exosomes at diagnosis, that these levels
decrease after induction chemotherapy and increase during consolidation chemotherapy. The exosome
levels remained elevated in AML patients whose leukemia recurred, and they normalized in patients
in long-term remission [6].
Other environmental stress conditions, including ionizing radiation, also influence exosome
secretion. Exosomes derived from irradiated cells can transfer radiation-mediated signals to other
cells, transferring radiation-related effects to the recipient cells, which have not been exposed to
radiation [62]. Exosomes derived from irradiated cells also show an altered behavior in functional
studies: they promote survival of irradiated cells [63]. Mechanistically, it was shown that irradiation
induces pathways of exosome secretion regulated by TSAP6, which is transcriptionally regulated by
p53. Thus, the rate of exosome secretion and exosome composition are influenced by DNA damage
caused by irradiation [62]. Abramowicz et al. reported that the cargo of exosomes produced by
head and neck cancer cells was altered by ionizing radiation. The exosomes produced by the treated
cells contained 472 proteins, whose abundance was significantly affected by radiation delivered at
different doses. Most of these proteins were upregulated and only 47 proteins were downregulated [64].
Low-level laser irradiation (LLLI) was described to influence angiogenesis in vitro and in vivo. Bagheri
et al. showed that LLLI at high power density directly affected endothelial cells by promoting exosome
release [65]. This finding indicates that the ratio of tumor cell-derived to endothelial cell-derived
exosomes in the TME and/or in the blood might be modulated by LLLI.
5. Conclusions
The process of exosome packaging and production in the endocytic compartment of the producer
cell is characterized by substantial plasticity, which is mainly modulated by stress-related environmental
factors. The analysis of the exosome cargo emerges as a promising diagnostic/prognostic tool and is
of great current interest, because exosomes mimic the content of parental cells in their environment.
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However, no “gold standard” for exosome isolation exists, and the exosome nomenclature remains
undefined. Validation of promising findings reported for exosomes by numerous investigators is not
possible until a uniformly defined methodology for their isolation and characterization is in place. This
is a major challenge facing the field, and while it is being addressed by introduction and evaluation
of novel technologies, the results of studies with EVs, including exosomes, remain open to criticism.
It is to be expected that the existing limitations in studies of exosomes will soon be resolved and
will confirm the roles exosomes play as messengers of intercellular signaling and as biomarkers of
impending disease states.
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